The DOI matches its Crossref record; 68 of the 68 references it cites were found in a registry or an index.
The somatic mutation profiles of 2,433 breast cancers refine their genomic and transcriptomic landscapes
Open accessAbstract
The genomic landscape of breast cancer is complex, and inter- and intra-tumour heterogeneity are important challenges in treating the disease. In this study, we sequence 173 genes in 2,433 primary breast tumours that have copy number aberration (CNA), gene expression and long-term clinical follow-up data. We identify 40 mutation-driver (Mut-driver) genes, and determine associations between mutations, driver CNA profiles, clinical-pathological parameters and survival. We assess the clonal states of Mut-driver mutations, and estimate levels of intra-tumour heterogeneity using mutant-allele fractions. Associations between PIK3CA mutations and reduced survival are identified in three subgroups of ER-positive cancer (defined by amplification of 17q23, 11q13–14 or 8q24). High levels of intra-tumour heterogeneity are in general associated with a worse outcome, but highly aggressive tumours with 11q13–14 amplification have low levels of intra-tumour heterogeneity. These results emphasize the importance of genome-based stratification of breast cancer, and have important implications for designing therapeutic strategies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
The Genome Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data
McKenna, A., Hanna, M., Banks, E., Sivachenko, A., Cibulskis, K., Kernytsky, A., Garimella, K., Altshuler, D., Gabriel, S., Daly, M., et al. (2010) · Genome Research · doi:10.1101/gr.107524.110 · Cited by 27,895
Cerami, E., Gao, J., Dogrusoz, U., Gross, B. E., Sumer, S. O., Aksoy, B. A., Jacobsen, A., Byrne, C. J., Heuer, M. L., Larsson, E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0095 · Cited by 17,455
Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
Gao, J., Aksoy, B. A., Dogrusoz, U., Dresdner, G., Gross, B., Sumer, S. O., Sun, Y., Jacobsen, A., Sinha, R., Larsson, E., et al. (2013) · Science Signaling · doi:10.1126/scisignal.2004088 · Cited by 15,160
ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data
Wang, K., Li, M., & Hakonarson, H. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkq603 · Cited by 14,621
Nishimura, R., Osako, T., Nishiyama, Y., Tashima, R., Nakano, M., Fujisue, M., Toyozumi, Y., & Arima, N. (2013) · Oncology · doi:10.1159/000353099 · Cited by 13,166
Comprehensive molecular portraits of human breast tumours
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11412 · Cited by 12,129
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
Vogelstein, B., Papadopoulos, N., Velculescu, V. E., Zhou, S., Diaz, L. A., & Kinzler, K. W. (2013) · Science · doi:10.1126/science.1235122 · Cited by 7,863
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
Cited by
A living biobank of breast cancer organoids captures disease heterogeneity
Sachs, N., de Ligt, J., Kopper, O., Gogola, E., Bounova, G., Weeber, F., Balgobind, A. V., Wind, K., Gracanin, A., Begthel, H., et al. (2018) · Cell · doi:10.1016/j.cell.2017.11.010 · Cited by 1,973
Garrido-Castro, A. C., Lin, N. U., & Polyak, K. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-1177 · Cited by 1,451
Association analysis identifies 65 new breast cancer risk loci
Michailidou, K., Lindström, S., Dennis, J., Beesley, J., Hui, S., Kar, S., Lemaçon, A., Soucy, P., Glubb, D., Rostamianfar, A., et al. (2017) · Nature · doi:10.1038/nature24284 · Cited by 1,413
Self-citationTreatment landscape of triple-negative breast cancer — expanded options, evolving needs
Bianchini, G., De Angelis, C., Licata, L., & Gianni, L. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00565-2 · Cited by 1,382
Chemoresistance Evolution in Triple-Negative Breast Cancer Delineated by Single-Cell Sequencing
Kim, C., Gao, R., Sei, E., Brandt, R., Hartman, J., Hatschek, T., Crosetto, N., Foukakis, T., & Navin, N. E. (2018) · Cell · doi:10.1016/j.cell.2018.03.041 · Cited by 1,104
The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers
Razavi, P., Chang, M. T., Xu, G., Bandlamudi, C., Ross, D. S., Vasan, N., Cai, Y., Bielski, C. M., Donoghue, M. T. A., Jonsson, P., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.08.008 · Cited by 996
Bartoschek, M., Oskolkov, N., Bocci, M., Lövrot, J., Larsson, C., Sommarin, M., Madsen, C. D., Lindgren, D., Pekar, G., Karlsson, G., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-07582-3 · Cited by 826
Capivasertib in Hormone Receptor–Positive Advanced Breast Cancer
Turner, N. C., Oliveira, M., Howell, S. J., Dalenc, F., Cortes, J., Gomez Moreno, H. L., Hu, X., Jhaveri, K., Krivorotko, P., Loibl, S., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2214131 · Cited by 813
Deciphering breast cancer: from biology to the clinic
Nolan, E., Lindeman, G. J., & Visvader, J. E. (2023) · Cell · doi:10.1016/j.cell.2023.01.040 · Cited by 730
Molecular landmarks of tumor hypoxia across cancer types
Bhandari, V., Hoey, C., Liu, L. Y., Lalonde, E., Ray, J., Livingstone, J., Lesurf, R., Shiah, Y.-J., Vujcic, T., Huang, X., et al. (2019) · Nature Genetics · doi:10.1038/s41588-018-0318-2 · Cited by 678
Multi-omic machine learning predictor of breast cancer therapy response
Sammut, S.-J., Crispin-Ortuzar, M., Chin, S.-F., Provenzano, E., Bardwell, H. A., Ma, W., Cope, W., Dariush, A., Dawson, S.-J., Abraham, J. E., et al. (2022) · Nature · doi:10.1038/s41586-021-04278-5 · Cited by 654
Self-citationLee, K.-M., Giltnane, J. M., Balko, J. M., Schwarz, L. J., Guerrero-Zotano, A. L., Hutchinson, K. E., Nixon, M. J., Estrada, M. V., Sánchez, V., Sanders, M. E., et al. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2017.09.009 · Cited by 650
O'Leary, B., Cutts, R. J., Liu, Y., Hrebien, S., Huang, X., Fenwick, K., André, F., Loibl, S., Loi, S., Garcia-Murillas, I., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0264 · Cited by 650
The PI3K-AKT-mTOR Pathway and Prostate Cancer: At the Crossroads of AR, MAPK, and WNT Signaling
Shorning, B. Y., Dass, M. S., Smalley, M. J., & Pearson, H. B. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21124507 · Cited by 616
Polak, P., Kim, J., Braunstein, L. Z., Karlic, R., Haradhavala, N. J., Tiao, G., Rosebrock, D., Livitz, D., Kübler, K., Mouw, K. W., et al. (2017) · Nature Genetics · doi:10.1038/ng.3934 · Cited by 531
Self-citationMolecular Classification of Breast Cancer
Tsang, J. Y. S., & Tse, G. M. (2020) · Advances in Anatomic Pathology · doi:10.1097/pap.0000000000000232 · Cited by 556
Tang, A. D., Soulette, C. M., van Baren, M. J., Hart, K., Hrabeta-Robinson, E., Wu, C. J., & Brooks, A. N. (2020) · Nature Communications · doi:10.1038/s41467-020-15171-6 · Cited by 509
Kim, S.-B., Dent, R., Im, S.-A., Espié, M., Blau, S., Tan, A. R., Isakoff, S. J., Oliveira, M., Saura, C., Wongchenko, M. J., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30450-3 · Cited by 478
Karaayvaz, M., Cristea, S., Gillespie, S. M., Patel, A. P., Mylvaganam, R., Luo, C. C., Specht, M. C., Bernstein, B. E., Michor, F., & Ellisen, L. W. (2018) · Nature Communications · doi:10.1038/s41467-018-06052-0 · Cited by 476
PI3K inhibitors are finally coming of age
Vanhaesebroeck, B., Perry, M. W. D., Brown, J. R., André, F., & Okkenhaug, K. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00209-1 · Cited by 476
Glucocorticoids promote breast cancer metastasis
Obradović, M. M. S., Hamelin, B., Manevski, N., Couto, J. P., Sethi, A., Coissieux, M.-M., Münst, S., Okamoto, R., Kohler, H., Schmidt, A., et al. (2019) · Nature · doi:10.1038/s41586-019-1019-4 · Cited by 462
The Landscape of Targeted Therapies in TNBC
Vagia, E., Mahalingam, D., & Cristofanilli, M. (2020) · Cancers · doi:10.3390/cancers12040916 · Cited by 450
Bruna, A., Rueda, O. M., Greenwood, W., Batra, A. S., Callari, M., Batra, R. N., Pogrebniak, K., Sandoval, J., Cassidy, J. W., Tufegdzic-Vidakovic, A., et al. (2016) · Cell · doi:10.1016/j.cell.2016.08.041 · Cited by 448
Self-citationO’Leary, B., Hrebien, S., Morden, J. P., Beaney, M., Fribbens, C., Huang, X., Liu, Y., Bartlett, C. H., Koehler, M., Cristofanilli, M., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-03215-x · Cited by 414
Bareche, Y., Venet, D., Ignatiadis, M., Aftimos, P., Piccart, M., Rothe, F., & Sotiriou, C. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy024 · Cited by 382
Frequency and spectrum of PIK3CA somatic mutations in breast cancer
Martínez-Sáez, O., Chic, N., Pascual, T., Adamo, B., Vidal, M., González-Farré, B., Sanfeliu, E., Schettini, F., Conte, B., Brasó-Maristany, F., et al. (2020) · Breast Cancer Research · doi:10.1186/s13058-020-01284-9 · Cited by 380
Profiling human breast epithelial cells using single cell RNA sequencing identifies cell diversity
Nguyen, Q. H., Pervolarakis, N., Blake, K., Ma, D., Davis, R. T., James, N., Phung, A. T., Willey, E., Kumar, R., Jabart, E., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-04334-1 · Cited by 379
Evolving concepts in HER2 evaluation in breast cancer: Heterogeneity, HER2-low carcinomas and beyond
Marchiò, C., Annaratone, L., Marques, A., Casorzo, L., Berrino, E., & Sapino, A. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.02.016 · Cited by 377
Friedman, G., Levi-Galibov, O., David, E., Bornstein, C., Giladi, A., Dadiani, M., Mayo, A., Halperin, C., Pevsner-Fischer, M., Lavon, H., et al. (2020) · Nature Cancer · doi:10.1038/s43018-020-0082-y · Cited by 347
Self-citationTargeting the PI3-kinase pathway in triple-negative breast cancer
Pascual, J., & Turner, N. C. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz133 · Cited by 333
Signaling Pathways in Cancer: Therapeutic Targets, Combinatorial Treatments, and New Developments
Yip, H. Y. K., & Papa, A. (2021) · Cells · doi:10.3390/cells10030659 · Cited by 316
Imaging mass cytometry and multiplatform genomics define the phenogenomic landscape of breast cancer
Ali, H. R., Jackson, H. W., Zanotelli, V. R. T., Danenberg, E., Fischer, J. R., Bardwell, H., Provenzano, E., CRUK IMAXT Grand Challenge Team, Ali, H. R., Al Sa’d, M., et al. (2020) · Nature Cancer · doi:10.1038/s43018-020-0026-6 · Cited by 306
Self-citationMcDonald, B. R., Contente-Cuomo, T., Sammut, S.-J., Odenheimer-Bergman, A., Ernst, B., Perdigones, N., Chin, S.-F., Farooq, M., Mejia, R., Cronin, P. A., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aax7392 · Cited by 305
Self-citationThe NF1 somatic mutational landscape in sporadic human cancers
Philpott, C., Tovell, H., Frayling, I. M., Cooper, D. N., & Upadhyaya, M. (2017) · Human Genomics · doi:10.1186/s40246-017-0109-3 · Cited by 303
Jackson, M., Marks, L., May, G. H. W., & Wilson, J. B. (2018) · Essays in Biochemistry · doi:10.1042/ebc20170053 · Cited by 295
Comprehensive omic characterization of breast cancer in Mexican-Hispanic women
Romero-Cordoba, S. L., Salido-Guadarrama, I., Rebollar-Vega, R., Bautista-Piña, V., Dominguez-Reyes, C., Tenorio-Torres, A., Villegas-Carlos, F., Fernández-López, J. C., Uribe-Figueroa, L., Alfaro-Ruiz, L., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22478-5 · Cited by 291
Marked for death: Targeting epigenetic changes in cancer
Pfister, S. X., & Ashworth, A. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.256 · Cited by 288
Breast Cancer Molecular Stratification
Russnes, H. G., Lingjærde, O. C., Børresen-Dale, A.-L., & Caldas, C. (2017) · The American Journal of Pathology · doi:10.1016/j.ajpath.2017.04.022 · Cited by 280
Self-citationA Comprehensive Immunologic Portrait of Triple-Negative Breast Cancer
Liu, Z., Li, M., Jiang, Z., & Wang, X. (2018) · Translational Oncology · doi:10.1016/j.tranon.2018.01.011 · Cited by 275
Explaining a series of models by propagating Shapley values
Chen, H., Lundberg, S. M., & Lee, S.-I. (2022) · Nature Communications · doi:10.1038/s41467-022-31384-3 · Cited by 278
SALMON: survival analysis learning with multi-omics neural networks on breast cancer
Huang, Z., Zhan, X., Xiang, S., Johnson, T. S., Helm, B., Yu, C. Y., Zhang, J., Salama, P., Rizkalla, M., Han, Z., et al. (2019) · Frontiers in Genetics · doi:10.3389/fgene.2019.00166 · Cited by 262
“Breast invasive carcinoma patients have a 77% survival rate after 5 years and 44% survival rate after 15 years (Pereira et al., 2016), so developing accurate prognostic models could significantly improve risk stratification after diagnosis.”
BackgroundBreast tumor microenvironment structures are associated with genomic features and clinical outcome
Danenberg, E., Bardwell, H., Zanotelli, V. R. T., Provenzano, E., Chin, S.-F., Rueda, O. M., Green, A., Rakha, E., Aparicio, S., Ellis, I. O., et al. (2022) · Nature Genetics · doi:10.1038/s41588-022-01041-y · Cited by 274
Self-citationAlpelisib: First Global Approval
Markham, A. (2019) · Drugs · doi:10.1007/s40265-019-01161-6 · Cited by 270
PTEN Loss Mediates Clinical Cross-Resistance to CDK4/6 and PI3Kα Inhibitors in Breast Cancer
Costa, C., Wang, Y., Ly, A., Hosono, Y., Murchie, E., Walmsley, C. S., Huynh, T., Healy, C., Peterson, R., Yanase, S., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0830 · Cited by 270
Patient-derived xenograft (PDX) models in basic and translational breast cancer research
Dobrolecki, L. E., Airhart, S. D., Alferez, D. G., Aparicio, S., Behbod, F., Bentires-Alj, M., Brisken, C., Bult, C. J., Cai, S., Clarke, R. B., et al. (2016) · Cancer and Metastasis Reviews · doi:10.1007/s10555-016-9653-x · Cited by 267
Self-citationTumor mutational burden is a determinant of immune-mediated survival in breast cancer
Thomas, A., Routh, E. D., Pullikuth, A., Jin, G., Su, J., Chou, J. W., Hoadley, K. A., Print, C., Knowlton, N., Black, M. A., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1490854 · Cited by 262
ESO–ESMO 4th International Consensus Guidelines for Breast Cancer in Young Women (BCY4)
Paluch-Shimon, S., Cardoso, F., Partridge, A. H., Abulkhair, O., Azim, H. A., Bianchi-Micheli, G., Cardoso, M.-J., Curigliano, G., Gelmon, K. A., Harbeck, N., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.03.284 · Cited by 254
Samstein, R. M., Krishna, C., Ma, X., Pei, X., Lee, K.-W., Makarov, V., Kuo, F., Chung, J., Srivastava, R. M., Purohit, T. A., et al. (2020) · Nature Cancer · doi:10.1038/s43018-020-00139-8 · Cited by 219
Landscape of G-quadruplex DNA structural regions in breast cancer
Hänsel-Hertsch, R., Simeone, A., Shea, A., Hui, W. W. I., Zyner, K. G., Marsico, G., Rueda, O. M., Bruna, A., Martin, A., Zhang, X., et al. (2020) · Nature Genetics · doi:10.1038/s41588-020-0672-8 · Cited by 223
Self-citationVariational autoencoders for cancer data integration: design principles and computational practice
Simidjievski, N., Bodnar, C., Tariq, I., Scherer, P., Andres Terre, H., Shams, Z., Jamnik, M., & Liò, P. (2019) · Frontiers in Genetics · doi:10.3389/fgene.2019.01205 · Cited by 145
Truong, D. D., Kratz, A., Park, J. G., Barrientos, E. S., Saini, H., Nguyen, T., Pockaj, B., Mouneimne, G., LaBaer, J., & Nikkhah, M. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-2293 · Cited by 149
Hypoxia-induced switch in SNAT2/SLC38A2 regulation generates endocrine resistance in breast cancer
Morotti, M., Bridges, E., Valli, A., Choudhry, H., Sheldon, H., Wigfield, S., Gray, N., Zois, C. E., Grimm, F., Jones, D., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1818521116 · Cited by 131
Arruabarrena-Aristorena, A., Maag, J. L. V., Kittane, S., Cai, Y., Karthaus, W. R., Ladewig, E., Park, J., Kannan, S., Ferrando, L., Cocco, E., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.08.003 · Cited by 130
Rajendran, B. K., & Deng, C.-X. (2017) · Oncotarget · doi:10.18632/oncotarget.17225 · Cited by 73
MASTL overexpression promotes chromosome instability and metastasis in breast cancer
Rogers, S., McCloy, R. A., Parker, B. L., Gallego-Ortega, D., Law, A. M. K., Chin, V. T., Conway, J. R. W., Fey, D., Millar, E. K. A., O’Toole, S., et al. (2018) · Oncogene · doi:10.1038/s41388-018-0295-z · Cited by 67
Zhang, G., Wang, Y., Chen, B., Guo, L., Cao, L., Ren, C., Wen, L., Li, K., Jia, M., Li, C., et al. (2019) · Annals of Translational Medicine · doi:10.21037/atm.2019.04.23 · Cited by 66
HDACs and the epigenetic plasticity of cancer cells: target the complexity
Brancolini, C., Gagliano, T., & Minisini, M. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108190 · Cited by 55
Kumegawa, K., Takahashi, Y., Saeki, S., Yang, L., Nakadai, T., Osako, T., Mori, S., Noda, T., Ohno, S., Ueno, T., et al. (2022) · npj Breast Cancer · doi:10.1038/s41523-022-00438-6 · Cited by 45
BRE/BRCC45 regulates CDC25A stability by recruiting USP7 in response to DNA damage.
Biswas, K., Philip, S., Yadav, A., Martin, B. K., Burkett, S., Singh, V., Babbar, A., North, S. L., Chang, S., & Sharan, S. K. (2018) · Nature Communications · doi:10.1038/s41467-018-03020-6 · Cited by 41
CRISPR screens identify gene targets at breast cancer risk loci
Tuano, N. K., Beesley, J., Manning, M., Shi, W., Perlaza-Jimenez, L., Malaver-Ortega, L. F., Paynter, J. M., Black, D., Civitarese, A., McCue, K., et al. (2023) · Genome Biology · doi:10.1186/s13059-023-02898-w · Cited by 30
Computed cancer interactome explains the effects of somatic mutations in cancers
Zhang, J., Pei, J., Durham, J., Bos, T., & Cong, Q. (2022) · Protein Science · doi:10.1002/pro.4479 · Cited by 31
Rlip Depletion Suppresses Growth of Breast Cancer
Bose, C., Yadav, S., Singhal, S. S., Singhal, J., Hindle, A., Lee, J., Cheedella, N. K. S., Rehman, S., Layeequr Rahman, R., Jones, C., et al. (2020) · Cancers · doi:10.3390/cancers12061446 · Cited by 10
Yang, X., Ma, X., Zhao, T., Croucher, D. R., Nguyen, E. V., Clark, K. C., Hu, C., Latham, S. L., Bayly-Jones, C., Nguyen, B. V., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-57046-8 · Cited by 9
Liu, S., Liang, Z., Wang, Y., Ren, Y., Gu, Y., Qiao, Y., He, H., Li, Y., Cheng, Y., & Liu, Y. (2024) · Biotechnology Journal · doi:10.1002/biot.202300560 · Cited by 1
Metadata
- Authors
- Pereira, B., Chin, S.-F., Rueda, O. M., Vollan, H.-K. M., Provenzano, E., Bardwell, H. A., Pugh, M., Jones, L., Russell, R., Sammut, S.-J., Tsui, D. W. Y., Liu, B., Dawson, S.-J., Abraham, J., Northen, H., Peden, J. F., Mukherjee, A., Turashvili, G., Green, A. R., McKinney, S., Oloumi, A., Shah, S., Rosenfeld, N., Murphy, L., Bentley, D. R., Ellis, I. O., Purushotham, A., Pinder, S. E., Børresen-Dale, A.-L., Earl, H. M., Pharoah, P. D., Ross, M. T., Aparicio, S., & Caldas, C.
- Venue
- Nature Communications
- Published
- 2016-05-10
- Volume
- 7
- Issue
- 1
- Pages
- 11479-11479
- ISSN
- 2041-1723 (ISSN-L)
- OpenAlex
- W2375577403
- Cited by
- 1,717
- References
- 68
- FWCI
- 52.65
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.